Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
2.050
+0.220 (12.02%)
Mar 16, 2026, 11:35 AM EDT - Market open
Chemomab Therapeutics Stock Forecast
CMMB's stock price has decreased by -64.01% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Chemomab Therapeutics stock has a target of 25, which predicts a 1,119.51% increase from the current stock price of 2.05.
Price Target: $25 (+1,119.51%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 27, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Chemomab Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $25 | Buy | Maintains | $10 → $25 | +1,119.51% | Aug 27, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $44 → $40 | Buy | Maintains | $44 → $40 | +1,851.22% | May 16, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $16 → $28 | Strong Buy | Maintains | $16 → $28 | +1,265.85% | Feb 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $52 → $44 | Buy | Reiterates | $52 → $44 | +2,046.34% | Nov 15, 2024 |
| Maxim Group | Maxim Group | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +680.49% | May 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.56
from -3.11
EPS Next Year
-1.84
from -1.56
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.61 | -1.89 | ||||
| Avg | -1.56 | -1.84 | ||||
| Low | -1.50 | -1.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.